Biodexa Pharmaceuticals PLC ADR美股招股说明书(2026-08-05版)

BIODEXA PHARMACEUTICALS PLC 170,150 Ordinary Shares Representing 3,403 American Depositary Shares This prospectus supplement No. 2 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our RegistrationStatement on Form F-1, as amended, effective as of March 30, 2026 (the “Prospectus”), related to the resale by the selling shareholdersidentified in the Prospectus of up to an aggregate of 170,150 of our ordinary shares, nominal value £0.000001 per share, represented by 3,403American Depositary Shares (the “Depositary Shares”). This Prospectus Supplement is being filed in order to incorporate into and include in the Prospectus the information contained in ourattached Report on Form 6-K, filed with the Securities and Exchange Commission (the “SEC”) on July 29, 2026. This Prospectus Supplement should be read in conjunction with the Prospectus and is qualified by reference to the Prospectus except tothe extent that the information in this Prospectus Supplement supersedes the information contained therein. Our Depositary Shares are listed on the NASDAQ Capital Market under the symbol “BDRX.” The last reported closing price ofDepositary Shares on the NASDAQ Capital Market on August 3, 2026 was $1.42. Investing in our securities involves risks. See “Risk Factors” beginning on page 9 of the Prospectus and in the documentsincorporated by reference in the Prospectus for a discussion of the factors you should carefully consider before deciding to purchasethese securities. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of thesesecurities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. The date of this Prospectus Supplement is August 4, 2026. UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUERPURSUANT TO RULE 13a-16 OR 15d-16 OF THESECURITIES EXCHANGE ACT OF 1934 For the month of July 2026Commission File Number 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant’s name into English)1 Caspian Point,Caspian Way,Cardiff, CF10 4DQ, United Kingdom(Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-FForm 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): EXPLANATORY NOTE Results of General Meeting On July 29, 2026, Biodexa Pharmaceuticals PLC (the “Company”) announced that, at its general meeting of shareholders (the “GeneralMeeting”) held earlier that day, the Company’s shareholders had approved all four resolutions presented at the General Meeting, includingapproval of (i) a one-for-10,000 reverse stock split of the Company’s ordinary shares, nominal value £0.000001 per share (the “OrdinaryShares”), (ii) the allotment of up to £25,000,000 for future share issuances through the Company’s annual general meeting in 2029, and (iii)approval and adoption of new articles of association to reflect the transactions approved at the General Meeting (the “Articles of Association”). The reverse stock split is expected to be effective as of July 30, 2026. Concurrently with the effectiveness of the reverse stock split, theratio of Ordinary Shares per the Company’s American Depositary Shares (“ADS”) will also change by a factor of 10,000, from one ADS per500,000 Ordinary Shares to a new ratio of one ADS per 50 Ordinary Shares. The change in ratio of Ordinary Shares to ADSs will not result in, orhave the effect of, a reverse split of the ADSs and the proportional ownership of holders of Ordinary Shares and/or ADSs will not change. A copy of the new Articles of Association are attached hereto as Exhibit 3.1 and incorporated herein by reference. The information under the heading “Results of General Meeting” of this Report on Form 6-K, including Exhibit 3.1, shall be deemed tobe incorporated by reference into the registration statements on FormS-8 (File No. 333-209365) and FormF-3 (File No. 333-290554) of theCompany (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this reportis filed, to the extent not superseded by documents or reports subsequently filed or furnished. Other Events On July 29, 2026, the Company issued a press release announcing the results of the General Meeting, a copy of which is furnished asExhibit 99.1 and incorporated herein by reference. The information in the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section18 of theSecurities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemedincorporated by reference in any filing made by the Company under the Securities Act of 1933, a